Prakhar Agrawal (Cantor Fitzgerald) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Prakhar Agrawal's stock ratings?

About 50% of Prakhar's ratings were profitable over a one-year hold, with an average return of +31.1% per rating, measured by 13Foresight from historical prices.

Q: How is Prakhar ranked?

Prakhar Agrawal is ranked #1486 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Prakhar Agrawal

CANT

Prakhar Agrawal

Cantor Fitzgerald

Wall Street Analyst

★★★☆☆

#1486

on 13Foresight · ranked by our own returns

55%

Success Rate

+25.5%

Average Return

11 of 20 calls profitable · +5.9% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 55% of Prakhar Agrawal's ratings turned a profit when each position was held for 2 year — averaging +25.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

18 Buy 5 Hold 0 Sell

Prakhar's Stock Coverage 25 ratings · 2026-06-20

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	2-Yr Return
GPCR Structure Therapeutics, Inc. Sponsored ADR	Jun 07, 2026	BUY	Strong Buy +132.5% avg upside 17 analysts	$101.00 126.89% Upside	·
STTK Shattuck Labs	Apr 27, 2026	BUY	Strong Buy +369.1% avg upside 14 analysts	—	-43.9%
ZLDPF Zealand Pharma	Mar 06, 2026	HOLD	Buy +91.6% avg upside 11 analysts	—	·
MANE Veradermics, Incorporated	Mar 01, 2026	BUY	Strong Buy +31.9% avg upside 6 analysts	—	·
TVTX Travere Therapeutics	Feb 20, 2026	BUY	Strong Buy -16.0% avg upside 22 analysts	—	+71.2%
MLTX MoonLake Immunotherapeutics	Dec 04, 2025	BUY	Strong Buy +51.6% avg upside 20 analysts	—	+28.0%
EVMN Evommune, Inc.	Dec 01, 2025	BUY	Strong Buy +134.6% avg upside 12 analysts	—	+1.8%
MDGL Madrigal Pharmaceuticals	Nov 04, 2025	BUY	Strong Buy -5.8% avg upside 31 analysts	—	+8.1%
ACRS Aclaris Therapeutics	Oct 15, 2025	BUY	Strong Buy +122.5% avg upside 15 analysts	—	+123.8%
ORIC Oric Pharmaceuticals	Sep 26, 2025	BUY	Strong Buy +180.3% avg upside 19 analysts	—	-25.6%
ATYR aTyr Pharma	Sep 15, 2025	HOLD	Buy +2023.9% avg upside 17 analysts	—	-48.8%
AVTX Avalo Therapeutics	Aug 15, 2025	BUY	Strong Buy +265.1% avg upside 19 analysts	—	+81.3%
ARDX Ardelyx	Jul 07, 2025	BUY	Strong Buy +124.0% avg upside 21 analysts	—	+27.4%
ROIV Roivant Sciences	Jun 18, 2025	BUY	Strong Buy +2.5% avg upside 17 analysts	—	+172.7%
ARWR Arrowhead Pharmaceuticals	May 13, 2025	BUY	Strong Buy -19.2% avg upside 26 analysts	—	+387.7%
TGTX TG Therapeutics	Mar 03, 2025	BUY	Strong Buy -34.4% avg upside 19 analysts	—	+46.8%
KROS Keros Therapeutics	Jan 21, 2025	HOLD	Strong Buy +139.0% avg upside 21 analysts	—	-8.0%
EQ Equillium	Aug 11, 2023	BUY	Strong Buy +181.9% avg upside 14 analysts	$2.80 8.28% Downside	+9.9%
ALGS Aligos Therapeutics	Mar 17, 2023	HOLD	Strong Buy +773.1% avg upside 11 analysts	—	-64.6%
NEXI NexImmune	Mar 17, 2023	HOLD	Buy +7499900.0% avg upside 4 analysts	—	·
TCRT Alaunos Therapeutics	Jan 10, 2023	BUY	Buy +604.3% avg upside 13 analysts	$3.50 62.85% Upside	-98.6%
IRD Opus Genetics	Sep 12, 2022	BUY	Strong Buy +154.5% avg upside 23 analysts	$23.00 465.10% Upside	·
PHAT Phathom Pharmaceuticals	Oct 18, 2021	BUY	Strong Buy +163.8% avg upside 14 analysts	$62.00 469.92% Upside	-67.7%
ARQT Arcutis Biotherapeutics	Sep 21, 2021	BUY	Strong Buy +49.6% avg upside 14 analysts	$44.00 67.88% Upside	-74.8%
ALDX Aldeyra Therapeutics	Aug 05, 2021	BUY	Strong Buy +713.6% avg upside 21 analysts	$22.00 1022.39% Upside	-16.1%

🔒 20 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Prakhar Agrawal — Frequently Asked Questions

How accurate are Prakhar Agrawal's stock ratings?

Based on the calls 13Foresight could measure, about 50% of Prakhar's ratings were profitable over a one-year hold, with an average return of +31.1% per rating, or +18.4% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Prakhar ranked on 13Foresight?

Prakhar Agrawal is currently ranked #1486 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Prakhar cover?

Prakhar most recently has ratings on GPCR, STTK, ZLDPF, MANE, TVTX, MLTX, EVMN, MDGL, ACRS, ORIC, ATYR, AVTX and 13 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!